ChemoCentryx's novel Crohn's drug passes first stage of Phase II/III trial
This article was originally published in Scrip
Executive Summary
Initial results from a Phase II/III trial show that ChemoCentryx's novel lead compound Traficet-EN (CCX282-B), which is being co-developed with GlaxoSmithKline, demonstrates preliminary efficacy and good tolerability for patients with moderate to severe Crohn's disease. Traficet-EN is an oral antagonist of the CCR9 chemokine receptor.